GRAIL and Intermountain Healthcare Expand Partnership to Offer Galleri Multi-Cancer Early Detection Blood Test to Eligible Patients in Utah

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Intermountain Healthcare announced that Galleri, GRAIL’s groundbreaking multi-cancer early detection (MCED) blood test, will be offered as a complement to existing single cancer screenings to help advance the delivery of cancer care through early detection. Starting this month, Intermountain will offer the Galleri test to eligible health system patients at elevated risk for cancer, such as adults over 50 years old or with additional risk factors. In addition, the test will be available to eligible employees and their families who are enrolled in a company-sponsored health plan.

Latest Aithority Insights: DeepSig Publishes Milestone Report on AI/ML Improved 5G Open vRAN

“We are pleased to be expanding our partnership with Intermountain, a recognized leader in healthcare innovation, to expand its cancer screening capabilities with MCED,” said Josh Ofman, MD, MSHS, president and chief medical officer at GRAIL.

“When it comes to cancer, we promote proactive measures through preventive screening wherever possible because it leads to better outcomes,” said Dr. Naresh Agarwal, associate chief medical officer for primary care at Intermountain Healthcare. “The continuing partnership with GRAIL provides us with additional resources to detect cancer in its early, more treatable stages, directly aligning with our commitment to help people live the healthiest lives possible.”

Early detection is known to improve cancer outcomes, yet, today, most cancer is detected too late because only five cancer types have recommended screenings – breast, cervical, colon, lung and prostate cancers. The Galleri test is the first-of-its-kind multi-cancer early detection blood test available. Using advanced genomics and machine learning, in a clinical study, the Galleri test was able to detect signals across more than 50 types of cancer, more than 45 of which lack recommended screening tests, with a low false positive rate of less than 1%. The test also can determine where in the body the cancer signal comes from with high accuracy.

Intermountain, the largest private employer in Utah, is a not-for-profit health system with 33 hospitals and more than 3,800 physicians. The system serves residents with hospitals and clinics in seven states and additional operations across the western United States.

Browse The Complete News About Aithority : GrAI Matter Labs Unveils Life-Ready AI with GrAI VIP at GLOBAL INDUSTRIE

“We are pleased to be expanding our partnership with Intermountain, a recognized leader in healthcare innovation, to expand its cancer screening capabilities with MCED,” said Josh Ofman, MD, MSHS, president and chief medical officer at GRAIL. “Intermountain is a partner in the interventional PATHFINDER study evaluating the implementation and performance of the Galleri test in a clinical care setting and we’re grateful for their ongoing commitment to continuing to build the body of clinical evidence for the Galleri test. We applaud Intermountain’s forward-thinking approach to patient care so that, together, we can make progress against this devastating disease.”

Initial results from PATHFINDER were presented at the 2021 American Society of Clinical Oncology (ASCO), demonstrating that the performance of the Galleri test was consistent with findings from previous observational studies and underscoring the potential real-world ability of the Galleri test to find deadly cancers earlier. Final results from PATHFINDER will be presented at a medical meeting later this year.

Read More About Aithority News : SirionLabs Achieves SAP-Certified Integration with Cloud Solutions from SAP

[To share your insights with us, please write to sghosh@martechseries.com]